Tag: Circulation


Publication Review: Amin Analysis on Impella and IABP

Review of Trends, Variation and Outcomes in Impella® Use Dr. Seth Bilazarian, Abiomed’s Chief Medical Officer, provides a review of the observational analysis published in Circulation and presented at AHA 2019 by Amin, et al., comparing Impella to IABP. Dr. Bilazarian notes that the study is an observational, non-FDA audited analysis that is fundamentally flawed … Continue reading “Publication Review: Amin Analysis on Impella and IABP”

Use of Impella® Device During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury

Patients undergoing complex coronary revascularization are at risk for periprocedural and postprocedural acute kidney injury (AKI), a complication which correlates with an increased risk of death, major bleeding, and myocardial infarction (MI).1 A reduction in cardiac output and renal hypoperfusion, which in turn leads to a decrease in glomerular filtration rate, may partly explain the … Continue reading “Use of Impella® Device During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury”

Optimizing Cardiovascular Care in Accordance with the Body’s Internal “Clock”

Key Takeaways

  • Timing medical therapy to the body’s circadian rhythms may play a key role in improving treatment outcomes among patients with heart failure, myocardial infarction, and hypertension.
The study of circadian rhythms as it relates to human health has expanded in recent years, with a large focus devoted to utilizing knowledge regarding the body’s “internal clock” for improving the treatment of cardiovascular-related therapies. The circadian rhythms are regulated by the suprachiasmatic nucleus, a “master clock” in the hypothalamus that responds to light and manages the expression of genes that are active at varying times throughout the day and night. Exposure to artificial light during the evenings, such as during shift work or sleep deprivation, can disrupt circadian rhythms and lead to the desynchronization of gene expression. This has been consistently linked to cardiovascular disease.1,2Continue readingOptimizing Cardiovascular Care in Accordance with the Body’s Internal “Clock”

PCI with Everolimus Eluting Stents vs CABG for Left Main Coronary Artery Disease: The EXCEL Trial

Key Takeaways

  • Coronary-artery bypass is a standard treatment of choice for left main coronary artery disease patients, but some trials suggest PCI with stenting could be a good alternative therapeutic option.
  • The EXCEL randomized trial found that complete revascularization via PCI with everolimus-eluting stents is noninferior to CABG for left-main CAD with respect to the study’s primary and secondary endpoints.
Patients with left main coronary artery disease (CAD) are at a significantly high risk for cardiovascular events due to vessel occlusion that compromises flow in up to three-fourths of the left ventricle. Bypass surgery had been the standard treatment of choice for left main CAD in the past, yet innovations and advancements in cardiology has led to the use of more refined and less invasive therapies. Continue readingPCI with Everolimus Eluting Stents vs CABG for Left Main Coronary Artery Disease: The EXCEL Trial

CABG Beneficial for Older Patients with Heart Failure and Left Ventricular Systolic Dysfunction

Ten-Year Follow-Up Analysis of STICH Trial Key Takeaways CABG lowered cardiovascular-related mortality for heart failure patients in the STICH trial. Increasing age tends to diminish benefits received from surgical revascularization. Cardiovascular death was higher among younger patients enrolled in STICH at 10 years’ follow-up. While mortality increases with advancing age, CABG plus guideline-directed medical therapy … Continue reading “CABG Beneficial for Older Patients with Heart Failure and Left Ventricular Systolic Dysfunction”